At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
CHAMPS Study: Chronic HepAtitis C Management to ImProve OutcomeS
In Brief
A clinical study evaluating Usual care plus peer-mentors, Usual care plus incentives, and 1 other intervention for Hepatitis C Virus Infection, Response to Therapy of and Human Immunodeficiency Virus. Completed, enrolled 144 participants across 1 site.
Detailed Summary
This study is being done to compare three strategies to deliver HCV treatment with ledipasvir/sofosbuvir which is an approved therapy which is administered as one tablet by mouth daily for 12 weeks. The study population is persons living with HIV and hepatitis C virus (HCV) coinfection who also use drugs. Participants will be randomized into one of three treatment groups: 1. Usual care in the clinic. This treatment group will receive the standard of care for HCV treatment from their health care team. 2. Usual care plus peer-mentors. In addition to the usual care, this is an investigational strategy in which participants assigned to this group will be asked to interact with a peer-mentor who is someone who has been cured of their HCV infection. 3. Usual care plus incentives. In addition to the usual care, this is an investigational strategy in which participants assigned to this group will be given incentives after completing certain treatment goals during the course of the study. HCV treatment with ledipasvir/sofosbuvir is considered the standard of care for HCV and is recommended by experts in liver disease and infectious diseases.
Study Details
Timeline
Interventions
Participants are assigned a peer mentor for support before and after treatment for HCV with Harvoni.
Participants are given incentives after completing treatment goals.
Participants receive standard of care in the clinic from their health care team.